Medical device exit options: pick the deal path that matches regulatory and commercial reality
Boards and founders usually agree something should change long before they agree how. This page is a decision stack: compare instruments side-by-side, run the wizard if you like click-through guidance, and read static outcomes that do not require JavaScript. Use it to align executives and investors on vocabulary before counsel spends six figures drafting the wrong structure.
Operator note. If your device is cleared but under-commercialized, read the shelved-device regulatory guide before you promise a strategic multiple—buyers will diligence manufacturing restart and labeling continuity first.
Compare deal paths
Rows are simplified on purpose: every live deal blends timing, risk, and governance. Use the table to force a choice about what transfers now vs what can wait. Mixed instruments (e.g., distribution + call option, license + equity kick) are normal—your counsel papers them; this page helps you ask for the right shape.
Path
What transfers
Typical speed
Economics
When it fits
Acquisition (equity / substantially all)
Legal entity or substantially all assets: QMS scope, DHF/DMR where applicable, listings, contracts, people, full vigilance history.
Geo- or account-limited commercial lead; may include importer/OEM duties and marketing minimums.
Medium—depends on regulatory setup per country
Minimum purchase, rev share, tiered pricing
Global seller monetizes a region without local FTE load
OEM / private-label
Manufacturing under partner brand; batch release, change control, and supplier governance stay critical.
Medium—validation and transfer activities
Unit economics, NRE, capacity guarantees
Partner has brand/channel; manufacturer has validated production
Partnership / alliance
Milestones for development or market proof; shared governance; may include options on later M&A.
Highly variable—science and regulatory clocks dominate
Blended milestones + revenue or royalty
Neither side ready to price full acquisition yet
Mixed instruments buyers actually propose
Distribution or license now, call option on assets later if KPIs hit—bridges valuation disagreement with real PO data.
Regional exclusive with ROFR on acquisition—rewards the partner who funded launch while preserving seller exit optionality.
Asset purchase of a line with seller TSA + earnout tied to regulatory milestones—aligns buyer and seller on submission success, not just revenue.
Strategic investment + board observer + co-promote—lighter than full M&A when science risk remains.
Each pattern fails when data rights, exclusivity, and regulatory correspondence are vague. Negotiate those before you debate logos on the press release.
Deal path finder
Answer in order. This is a decision aid—not a substitute for counsel.
1) What is the primary goal?
2a) Is the value mostly one line—or the whole entity?
2b) Do you need a partner to manufacture, or mostly to sell?
2c) Are you willing to grant exclusivity in that geography?
Deal path starting points (same as the wizard, in plain HTML)
The interactive tool above is optional. Every recommendation below is already in this response—no JavaScript required to read it. Use these bullets as an executive summary you can paste into an internal memo.
Product-line / asset acquisition. You mainly need SKUs, documentation, and supply—not the entire company. Read medical device acquisitions for carve-out failure modes, then list or respond on the buyer interest board with explicit geography and deal shape.
Licensing / partnership economics. You are monetizing rights while keeping much of the QMS or file. Compare tradeoffs in the comparison table above, then list an opportunity with field/territory and regulatory correspondence expectations stated clearly.
OEM / private-label. Manufacturing capacity and change control are the product. Review distribution & OEM framing and scan buyer mandates on the board for partners who need finished goods, not brands.
Exclusive regional distribution. You need one accountable operator with performance teeth. Read distribution opportunities for minimums and vigilance splits, then publish geography and service expectations in your teaser.
Non-exclusive or pilot channel. Useful for testing demand before exclusivity—requires clean segmentation and conflict rules. Still route through distribution guidance; honesty about channel overlap saves months of false starts.
Practical recommendations by scenario
Need cash this year with minimal integration: prioritize distribution or licensing structures that monetize channel without moving the whole QMS—then revisit M&A with traction data.
Buyer is a direct competitor: assume hostile-grade regulatory diligence; line up RA/QA narrative, complaint history, and promotion review before management meetings (acquisitions guide).
Founder wants liquidity but core team must stay: whole-company sale with explicit retention and governance; avoid “asset light” stories that orphan batch release and vigilance owners (company for sale).
Device cleared but never scaled: prove manufacturing restart, supplier continuity, and labeling path before pitching strategic pricing—buyers model integration cost aggressively (shelved-device guide).
EU revenue is the prize: decide early whether you are selling rights, establishing an importer partnership, or moving economic-operator responsibility—each path has different timelines (distribution).
IP strong but channel weak: licensing or regional exclusives often beat premature M&A; keep control of regulatory correspondence until milestones clear.
Multiple SKUs but one hero product: consider line divestiture instead of wholeco to preserve seller operations and simplify reps (line vs company).
See current buyer demand
Mandates clarify which exit paths buyers are actually funding today.
Can we combine paths (e.g., distribution now, acquisition later)?
Yes—real deals often stack instruments: pilot distribution, option to acquire, milestone-based license fees, or a call on assets if KPIs hit. The failure mode is a verbal ‘we’ll figure out M&A later’ without data rights, valuation mechanics, exclusivity windows, and regulatory continuity spelled out.
Where does Cruxi fit if we already have a banker?
Deal Desk can be the controlled front door for inbound interest and teaser distribution while your banker runs formal process mechanics. Many teams use both—Cruxi for origination and discipline, bankers for buyer outreach breadth.
Which path is fastest to cash?
Often distribution or licensing—if you already have cleared product and just need channel. Acquisition is rarely the fastest cash path because diligence and reps negotiations take time. Speed without structure just moves risk to post-close.
What is the most common mistake when comparing these paths internally?
Treating them as mutually exclusive labels instead of a sequence. Teams argue M&A vs license in the abstract when the real question is what must transfer this year (cash, control, regulatory file, channel) and what can wait.
Cruxi Deal Desk connects listing owners and buyers with staged disclosure and workspace workflows. Publisher: Lo Khamis, Founder, Cruxi. This guide is operational, not legal or investment advice. Confirm regulatory and tax outcomes with qualified advisors before you sign.